November 14-16

Boston, MA, USA

Speakers

Expand/Collapse

Michael Holers
President of the International Complement Society & Scoville
Professor & Head, Division of Rheumatology, University of Colorado

Dr. Holers received his MD degree from Washington University School of Medicine in St. Louis. Following clinical training in rheumatology and a postdoctoral research fellowship in complement biology, he joined the faculty at Washington University in 1986. Dr. Holers moved to the University of Colorado in 1993 as the first Smyth Professor of Rheumatology, where he is now Head of the Division of Rheumatology. The focus of Dr. Holers’ complement research program has evolved from studying the molecular genetics of complement C3 receptors and membrane regulatory proteins and the in vivo roles of these proteins to the development of complement therapeutics.

Day One

Wednesday November 15 2017

15.30 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Individual Diseases

11.40 | Therapeutic Insights from Studies of Complement Activation Mechanisms at Local Tissue Sites

09.00 | Chairman’s Opening Remarks

Day Two

Thursday November 16 2017

16.15 | Chairman’s Closing Remarks

09.00 | Chairman’s Opening Remarks

Camille Bedrosian
SVP & CMO
Alexion Pharmaceuticals

Camille is the Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals. A medical oncologist and haematologist, she brings more than 25 years of academic medical practice, research and drug development expertise to this role. At Alexion, she has provided leadership for the development of drugs and drug candidates across therapeutic areas encompassing complement-mediated diseases, including for Alexion’s marketed terminal complement inhibitor eculizumab, as well as more recently, therapeutics in the metabolic disease area.

Day One

Wednesday November 15 2017

14.30 | Terminal Complement Inhibition for Refractory Generalize Myasthenia Gravis, a Neurological Disease Driven by Classical Complement Pathway Activation

Simon Read
CSO
Ra Pharma

Simon has been Chief Scientific Officer at Ra Pharma since April 2016. Prior to joining the company, he served as Vice President and Head of the Innovative Medicines Unit (IMU) at Grünenthal GmbH, a pharmaceutical company headquartered in Aachen, Germany from 2014 to 2016. Prior to that, Simon served as Vice President and Head of Global Biomedical Sciences at Grünenthal GmbH from 2011 to 2014. Before joining Grünenthal, he was the Director, Experimental Medicine and Biomarkers, Immunology with Roche Products/Genentech Inc. from 2008 to 2011. Simon has been a member of the Medical Research Council and Association of British Pharmaceutical Industry Steering Committee for the UK’s foremost Immunology Consortium since 2012. He has been a member of the Boston Children’s Hospital Technology Development Fund steering group since 2016. Simon received his B.Sc. in Physiology from University of Manchester, a M.Sc. from University of Southampton and a Ph.D. from University of Hertfordshire.

Cedric Francois
Founder, President & CEO
Apellis Pharmaceuticals

Dr. Francois is co-founder of Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, and has served as President and CEO since September 2009. Dr. Francois was previously co-founder of Potentia Pharmaceuticals, where he served as President and CEO. Dr. Francois received his M.D. from the University of Leuven, Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the Louisville face transplant team and of the research team that performed the first successful hand transplantation.

Day One

Wednesday November 15 2017

15.00 | Therapeutic Targeting of C3 to treat PNH, GA & Macular Degeneration

Eva-Maria Nichols
Head of Complement
GlaxoSmithKline

Eva was appointed Head of Complement at GSK's Chemokine, Cytokine and Complement Discovery Performance Unit in 2016, . The group's focus is pre-clinical target/disease validation in complement and development of novel functional assays. Eva joined GSK's C3 DPU back in 2014, working on the complement-focused early discovery pipeline. Eva completed her postgraduate and postdoctoral research at Newcastle University, UK. Eva’s research involved the generation and testing of recombinant Factor H molecules (“mini-FH”) and scFv fragments for drug-targeting to the glomerular basement membrane.  

Morning Workshop

Tuesday November 14 2017

09.00 |
Optimizing Complement-based Clinical Trial Design

Day Two

Thursday November 16 2017

15.15 | Approaches to Computational Modelling of the Complement System

Graham Parry
Senior Director of Translational Research
Bioverativ

Graham Parry is Sr. Director of Translational Research at Bioverativ (formerly True North)  and the scientific champion behind TNT009, a first-in-class humanized monoclonal antibody that inhibits the classical pathway specific serine protease, C1s. Graham has also been heavily involved with the interactions that have led to the orphan and breakthrough designation status of TNT009 for the treatment of cold agglutinin disease.

Day One

Wednesday November 15 2017

12.10 | TNT009 Prevents the Deposition of Complement Split Products on Cells and Tissues from Patients with Classical Pathway Mediated Diseases

Nader Najafian
Director of Clinical R&D
Alnylam Pharmaceuticals

Trained in Nephrology and Transplantation at Harvard Medical School, currently Lecturer at Harvard Medical School and Associate physician at Brigham and Women’s Hospital as well as Director of clinical research at Alnylam.

Day Two

Thursday November 16 2017

09.30 | Utilization of si-RNAs in Treatment of Complement-Mediated Diseases

David Apelian
CMO & EVP
Achillion Pharmaceuticals

Dr. Apelian leads the Achillion clinical development program for the oral complement factor D inhibitor platform and has more than 17 years of industry experience with a focus on hepatology immune-oncology, and infectious diseases. Previously, Dr. Apelian served in various senior R&D roles at Schering Plough, BMS, and GlobeImmune including clinical development, regulatory affairs, clinical immunology, companion diagnostics, target discovery, and preclinical research. Most recently,.Dr. Apelian was appointed to the board of directors of Eiger Biopharma.  Dr. Apelian completed his residency training in Pediatrics at New York Hospital, Cornell Medical Center, received his MD from the University of Medicine and Dentistry of New Jersey, his PhD in Biochemistry and BA from Rutgers University. He also holds an MBA from Quinnipiac University.

Day One

Wednesday November 15 2017

15.30 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Individual Diseases

Day Two

Thursday November 16 2017

12.30 | Targeting Factor D of the Complement Alternative Pathway Using Small Molcules for the Treatment of C3 Glomerulopathy (C3G)

Michael McCaleb
VP
Ionis Pharmaceuticals

During his career in pharmaceutical and biotech companies, Dr. McCaleb has led the discovery of over a dozen drugs that have advanced into development.  In addition, he has also played a major role in the clinical development of numerous drugs, several of them achieving international commercialization.  Most of his research has been devoted to the discovery of novel therapeutics for metabolic, neurological, ophthalmology and rare diseases.  Currently, Dr. McCaleb is Vice President of Clinical Development at Ionis Pharmaceuticals.  

Day Two

Thursday November 16 2017

13.30 | Panel: Comparing Current Approaches for Inhibition and Balancing Benefits and Risks by Assessing Optimum Inhibition Levels

13.00 | Pharmacodynamic Efficacy of the Complement Factor B (FB) Antisense Oligonucleotide, IONIS-FB-LRX

Niels Riedemann
CEO
InflaRX

Professor Riedemann is founder of InflaRx and has served as Chief Executive Officer since 2007. He is trained and board certified general surgeon and intensive care physician. He served as Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation and was heading several funded complement research grants as principle investigator.. His research has been awarded several national and international awards and he has published over 50 highly ranked scientific articles.

Day Two

Thursday November 16 2017

13.30 | Panel: Comparing Current Approaches for Inhibition and Balancing Benefits and Risks by Assessing Optimum Inhibition Levels

10.00 | Developing a Highly Potent and Selective First-in-Class Anti-C5a Antibody for Treatment of Inflammatory Diseases

Ashley Frazer-Abel
Exsera BioLabs Director
University of Colorado

Dr. Frazer-Abel directs a laboratory at the University of Colorado Denver that focuses on complement analysis.  The specialized testing utilized at Exsera advances novel research, as well as aiding in patient diagnoses and partnering in novel drug development.  Currently, Exsera is engaged in optimizing assays to meet the testing requirements of the growing number of complement therapeutics in development.  Dr. Frazer-Abel has over a decade of experience in the area of complement analysis, including the development of a number of novel assays that have been successful in answering previously unmet diagnostic needs.  She has also applied her complement expertise to acting as Principal Investigator for numerous non-clinical and clinical trials.  Dr. Frazer-Abel was part of the first US laboratory to participate in the International Complement Society Committee on Complement Assay Improvement and Standardization.  She continues to participate in that committee, currently as facilitator for the Activation Fragment Subcommittee.

Day One

Wednesday November 15 2017

10.10 | Panel: Assessing Optimum Dosage, Targeting, Endpoints and Sample Handling for Clinical Trials

09.10 | Identifying the Right Candidates - Complement Testing in the Era of Complement Specifics Therapeutics

Ted Yednock
CSO
Annexon Biosciences

Dr. Yednock joined Annexon Biosciences as Chief Scientific Officer in November 2013. Dr. Yednock was previously Chief Scientific Officer for Prothena Corporation, Head of Research for Elan Pharmaceuticals and a Scientist at Athena Neurosciences. While at Athena, he was the scientific inventor of Tysabri®, a blockbuster monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock earned his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California San Francisco.

Afternoon Workshop

Tuesday November 14 2017

13.00 |
Advancing Pre-Clinical Models: Development and Utilization of Effective Complement-mediated Disease Models

Sacha Zeerleder
Professor of Immunopathology
University of Amsterdam

Professor Sacha Zeerleder is an Internist-Hematologist at the Academic Medical Center and senior staff member at the department of immunopathology at Sanquin Research in Amsterdam (The Netherlands). He is the director of the hematopoietic stem cell transplantation program and medical head of the special hematology and transfusion laboratory of the Academic Medical Center. Zeerleder’s research is dedicated to the role of the innate immunity in hematological diseases. This mainly includes studies on mechanisms on how damage-associated molecular patterns (DAMPs) are released, the regulation hereof and how DAMPs induce systemic inflammation with a special interest in the role of plasma proteins (complement, coagulation) and plasma inhibitors herein. To study these concepts a main focus lies on diseases of systemic inflammation induced by infection (e.g. (neutropenic) sepsis), graft-vs-host disease or intravascular hemolysis such as autoimmune hemolytic anemia (AIHA), paroxysmal hemoglobinuria (PNH) and sickle cell disease.

Day One

Wednesday November 15 2017

10.10 | Panel: Assessing Optimum Dosage, Targeting, Endpoints and Sample Handling for Clinical Trials

09.40 | Enabling Confident Decision Making by Generating Powerful Data in Rare Disease Trials

Christopher Horvath
SVP, PreClinical Development
bluebird bio

Dr. Horvath is currently Senior Vice President of PreClinical Development at bluebird bio, a gene therapy company developing products for diseases related to genetic deficiencies.  He is currently responsible for pharmacology, bioassay development (nonclinical and clinical), PK, PD, toxicology and pathology. Christopher has worked on numerous products intended to modify complement pathways and complement-mediated diseases, and on several other products whose toxicity profiles included activation of complement pathways.

Day Two

Thursday November 16 2017

15.45 | Complement Activation as a Mediator of Anti-Complement Product Toxicities

Menno van Lookeren
Principal Scientist, Immunology
Genentech

Menno is a Principal Scientist in the Department of Immunology at Genentech Inc, overseeing R&D efforts in the area of ophthalmic diseases, including target identification, target validation and target delivery. He has leads several interdisciplinary programs in the area of ophthalmology, asthma and inflammatory bowel disease and is a co-inventor on over 20 published patents.

Day One

Wednesday November 15 2017

13.10 | The Role of Complement Therapeutics in the Treatment of Geographic Atrophy, the Advanced Form of Dry Age-Related Macular Degeneration

15.30 | Panel: Determining which Portion of the Complement Pathway is the Most Effective Intervention Point for Individual Diseases

Day Two

Thursday November 16 2017

13.30 | Panel: Comparing Current Approaches for Inhibition and Balancing Benefits and Risks by Assessing Optimum Inhibition Levels

Kishor Devalaraja
Senior Staff Scientist
Regeneron Pharmaceuticals

Dr. Kishor Devalaraja-Narashimha joined Regeneron as a postdoctoral scientist in the Cardiovascular and Renal therapeutic focus area, where he established preclinical research work to support target discovery for a number of kidney diseases. He currently works as a senior staff scientist in the company where he leads a team focusing on therapeutic target research and discovery, and drug development for both acute and chronic kidney diseases.

Rajendra Kumar-Singh
Founder & Managing Director, Hemera Biosciences │ Professor of
Developmental, Molecular and Chemical Biology, Tufts University

Rajendra Kumar-Singh, PhD is a Professor of Developmental, Molecular and Chemical Biology (DMCB) at Tufts University School of Medicine in Boston, MA and a co founder and VP of Hemera Biosciences Inc.  His research interests are in the development of therapies for retinal degeneration including age related macular degeneration, retinitis pigmentosa and diabetic retinopathy. Rajendra obtained his PhD from The University of Dublin, Trinity College in Ireland followed by a postodoctroal fellowship at the University of Michigan in Ann Arbor.  Rajendra then moved to the UCLA School of Medicine as a junior faculty and then as an Assistant Professor at The University of Utah. Rajendra joined Tufts University School of Medicine approximately 10 years ago where he moved through the ranks and is currently a tenured Professor in DMCB, Neuroscience and Ophthalmology.  The focus of Hemera Biosciences Inc. is to develop a gene therapy for the dry form of AMD, specifically by targeting the membrane attack complex of complement.  Phase I clinical trials are currently ongoing.

Day Two

Thursday November 16 2017

10.30 | Gene Therapy Targeting Complement for the Dry Form of Age-Related Macular Degeneration

Jörg Köhl
Director of the Institute for Systemic Inflammation Research
University of Lübeck

During the past 25 years,  Jörg’s laboratory has been interested in the role of complement in acute and chronic inflammatory diseases. More specifically, he is interested in the regulatory networks between complement and other arms of innate immunity and the impact of this cross-talk on innate and adaptive immune responses. The focus is on the anaphylatoxic peptides C3a and C5a and their G-Protein-coupled receptors in experimental models of allergic asthma, autoimmune diseases, transplantation and infections.

Day One

Wednesday November 15 2017

12.40 | The Anaphylatoxins and their Receptors as Targets in Inflammatory Diseases.

Kourous Rezaei
Senior Vice President, Medical Strategy
Ophthotech Corporation

Dr. Rezaei serves as the SVP, Medical Strategy of Ophthotech Corporation. He is a board certified ophthalmologist specializing in vitreoretinal diseases, and has been recognized with multiple awards, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. Dr. Rezaei is a voting member on the Board of Directors of the American Society of Retina Specialists (ASRS). Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.

Day Two

Thursday November 16 2017

12.00 | The Role of MAC Inhibition in Treating Retinal Diseases

Bärbel Rohrer
Professor and Endowed Chair, Department of Ophthalmology
Medical University of South Carolina

Dr. Bärbel (Barb) Rohrer is Professor and Endowed Chair in the Department of Ophthalmology at the Medical University of South Carolina and is an academic and innovative leader in diseases of the retina. Her lab is investigating mechanism of photoreceptor degeneration and neuroprotection, focusing on two areas: targeting complement activation in models of age-related macular degeneration and improving mitochondrial metabolism as a means to promote life-span in neurons. She holds eleven U.S. and international patents, with an additional 24 applications pending. Her IP provided the foundation for three start-up companies, one of which she co-founded. Dr. Rohrer has published >80 manuscripts; PI’d or Co-PI’d 40+ grants; and mentored 50+ trainees. In addition to the numerous intramural committees on which Dr. Rohrer serves, she is a Foundation Fighting Blindness Scientific Advisory Board member, member of multiple professional societies, including the Association for Research in Vision and Ophthalmology and the Society for Neuroscience, and elected member of the National Academy of Inventors.

Afternoon Workshop

Tuesday November 14 2017

13.00 |
Advancing Pre-Clinical Models: Development and Utilization of Effective Complement-mediated Disease Models

Kiran Nistala
Experimental Medicine Physician
GlaxoSmithKline

Kiran is an experimental medicine physician at GSK specialising in Drug Discovery Project Leadership and Early Phase Clinical Trial Design in the Complement, Chemokine and Cytokine Drug Performance Unit. His additional roles include leadership of the GSK Physician Community Global, membership of the GSK Immunotoxicology panel and Experimental Medicine Initiative steering committee, a collaboration between GSK, Astra Zeneca and University of Cambridge. His clinical activities are based at Great Ormond Street Hospital as an Honorary Consultant in Paediatric Rheumatology. Prior to joining GSK, Kiran trained as an academic paediatric rheumatologist with a focus on adaptive immune dysregulation in rheumatic disease.

Morning Workshop

Tuesday November 14 2017

09.00 |
Optimizing Complement-based Clinical Trial Design